With 9.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.24 million shares. The 52-week range on GENI shows that it touched its highest point at $10.33 and its lowest point at $4.91 during that stretch. It currently has a 1-year price target of $12.00. Beta for the stock currently stands at 2.15.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GENI was up-trending over the past week, with a rise of 11.63%, but this was up by 5.44% over a month. Three-month performance dropped to -4.71% while six-month performance rose 21.07%. The stock gained 30.94% in the past year, while it has gained 7.63% so far this year. A look at the trailing 12-month EPS for GENI yields -0.32 with Next year EPS estimates of 0.16. For the next quarter, that number is -0.05. This implies an EPS growth rate of 106.59% for this year and 796.28% for next year.
Float and Shares Shorts:
At present, 211.14 million GENI shares are outstanding with a float of 206.12 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GENI since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.14403 being high and -$0.14991 being low. For GENI, this leads to a yearly average estimate of -$0.14558. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.02. The average estimate for the next quarter is thus -$0.02.
Summary of Insider Activity:
Insiders traded GENI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
